The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium glucose co-transporter-2 inhibitors (SGLT2i), and statin-based regimen...
| Автори: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Інші автори: | |
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
Oxford University Press
2024
|